Abstract
Background Wastewater-based surveillance (WBS) on an institutional level was implemented during the COVID-19 pandemic, including carceral facilities. In this study of a mega-jail, we examined the relationship between COVID-19 diagnostic test results from jail residents and the PCR signal for SARS-CoV-2 detection in weekly samples of jail wastewater over a 28-week period.
Methods This study in a Georgia Jail (average population ∼2,700) was conducted October 2021-May 2022. Weekly on-site wastewater samples were collected (Moore Swabs) and tested for SARS-CoV-2 RNA using RTqPCR. The source of wastewater was identified using a tracer dye. The jail offered residents rapid antigen testing at entry. We conducted periodic mass screenings via RT-PCR of nasal swabs. We aggregated individual test data, calculated the Spearman correlation coefficient, and performed logistic regression to examine the relationship between the strength of the SARS-CoV-2 PCR signal (Ct value) in wastewater and the proportion of the jail population that tested positive for COVID-19.
Results Overall, 3770 individual nasal specimens were collected; 3.4% were COVID-positive. Weekly diagnostic test positivity ranged from 0%-29.5%. Dye tests demonstrated that a single wastewater collection point was sufficiently representative of the jail’s aggregate viral load. Twenty-five wastewater samples were collected. RT-qPCR Ct values for wastewater samples with SARS-CoV-2 RNA ranged from 28.1-39.9. A strong inverse correlation was observed between diagnostic test positivity and Ct value (r= −0.67, p < 0.01).
Conclusion WBS was shown to be an effective strategy for surveilling COVID-19 in a large jail. Strong partnerships with the jail administration are essential to the success of WBS surveillance.
Key Points
Monitoring the wastewater of a large jail can be effective for infectious disease surveillance.
To diagnose COVID-19, jail residents used self-collected nasal specimens.
There was a strong correlation between the prevalence of COVID-19 cases and the SARS-CoV-2 PCR signal in wastewater samples from the jail.
Competing Interest Statement
Bill and Melinda Gates Foundation NIH/NIHLB through Ceres Gilead Sciences NIH/NIAID Subcontract to Emory through Montefiore NIH/NIDA Ceres Nanosciences Cellex National Sciences Foundation National Commission on Correctional Health Care, National Sheriffs Association, Harris County Sheriffs Office, and California Department of Corrections and Rehabilitation National Commission on Correctional Health Care Honaria through third parties funded by Gilead, AbbVie, and Merck Harris County Sheriffs Office and California Department of Corrections and Rehabilitation Guardian Rockefeller Foundation Georgia Department of Public Health BioLytical
Funding Statement
This study was funded in whole or in part, by the Bill & Melinda Gates Foundation [INV-035562]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. Subcontract with Ceres Nanosciences for RADx Tech - Ceres Wastewater Testing NIH prime award 75N92021C00012
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Emory University waived ethical approval for this work. On 10/11/2021, the IRB reviewed the above-referenced submission and determined that the proposed activity is not research involving human subjects as defined by DHHS and FDA regulations. The protocol for this study only covers wastewater testing and collection of swabs from staff and residents; therefore, no other procedures are covered under this determination of not research with human subjects. IRB review and approval by this organization is not required. This determination applies only to the activities described in the IRB submission and does not apply should any substantial changes be made. If substantial changes are made and there are questions about whether these activities are research involving human in which the organization is engaged, please submit a new request to the IRB for a determination. You can create a modification by clicking Create Modification/CR within the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
